Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GE Aerospace (GE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GE Aerospace — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while GE Aerospace trades at $358.87 (market cap $374.84B). The key difference: GE Aerospace is far larger — about 9.4× Alnylam Pharmaceuticals, Inc.'s market cap, and GE Aerospace pays a 0.52% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GE | |
|---|---|---|
Market Cap | $39.89B | $374.84B |
Sector | Health | Industrials |
52-Week High | $491.22 | $378.68 |
52-Week Low | $278.09 | $255.42 |
Enterprise Value | $38.15B | $384.14B |
Dividend Yield | — | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GE Aerospace trades at $359.27, up 0.06% with a bullish technical signal supported by strong earnings beats and robust order growth. The company demonstrates improving fundamentals with revenue growth from $38.7B to $45.9B (2024-2025) and net income margin expansion to 18.98%. Recent defense contracts and commercial engine demand fuel positive sentiment, though elevated valuation ratios (P/E 44.63, P/S 7.9) warrant caution.
Outlook remains positive with 68.6% analyst buy ratings and $399.43 consensus target offering 11% upside. Key opportunities include aerospace demand surge and defense contract wins, while risks involve high debt levels ($19.27B total debt) and rich valuations that may limit near-term gains despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
